AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

PRE · NASDAQ · Medical - Diagnostics & Research

Prenetics Global

Sells IM8 nutrition products and CircleDNA consumer genetic testing worldwide.

$25.76

After-hours close−0.02 (−0.08%)

At close$25.78(−1.79%)

Something off on this page? Send us feedback.

Profile

Prenetics Global LimitedPREHealth Care

IM8 sells direct-to-consumer nutrition and longevity products, while CircleDNA provides consumer DNA testing. After divesting oncology, distribution, and cancer-detection holdings, the operating portfolio is concentrated on these two consumer-health brands.

IM8 is the flagship consumer-health brand, selling nutrition and longevity products directly to customers. It launched with Daily Ultimate Essentials and Daily Ultimate Longevity, and it began shipping across numerous countries and regions.

CircleDNA provides consumer DNA testing, carrying forward the company’s genetic-testing base alongside the newer supplement brand. The business has evolved from genetic testing and COVID-era diagnostics toward direct-to-consumer health and longevity.

Divestitures of ACT Genomics, Europa’s 3PL business, and the Insighta stake concentrated continuing operations on IM8 and CircleDNA. The company is Hong Kong-founded and Nasdaq-listed through a SPAC business combination, and the two-brand focus is its current operating structure.

Company facts

CEODanny Yeung

ListedMay 18, 2022

ExchangeNASDAQ

HeadquartersHong Kong, Hong Kong

CountryHong Kong

Employees98

CIK0001876431

ISINKYG722451229

Key statistics

Market cap$437.9M

EPS (ttm)−$4.16

P/E (ttm)−6.19

ROE-49.2%

P/B4.78

P/S3.07

Dividend yield—

Beta1.35vs XLV −0.39

Year to date +63.4% · Average volume (30d) 238.0K

Analysts

Price target, next 12 months$35.00+35.9%Median of 2 analysts · vs the Aug 28 close

ConsensusBuy2 of 2 analysts rate it buy or better

Ratings

Strong buyBuyHoldSellStrong sell

Target range

Last close $25.76

High$35.00+35.9%

Median$35.00+35.9%

Low$35.00+35.9%

12 months agoNowIn 12 months

Latest analyst notes

Date	Firm	Action	Rating	Target
Aug 27, 2026	B. Riley	Initiate	Buy
Jul 15, 2026	Lake Street	Reiterate	Buy	$35
Feb 11, 2026	Roth Capital	Target		$36

Earnings

EPS

Estimate−$0.77

ReportedDue Nov 9, 2026

Revenue

Estimate$63.1M

ReportedDue Nov 9, 2026

History

Report date	EPS est	EPS	Surprise	Revenue est	Revenue	Surprise	Next session
Aug 18, 2026Q2 FY26	−$0.84	−$0.53	+36.9%	$49.9M	$46.5M	−6.7%	+0.15%
Jun 10, 2026Q1 FY26	−$0.49	−$0.56	−14.3%	$36.0M	$36.0M	−0.1%	+7.48%
May 14, 2026Q1 FY26	−$0.49	−$1.14	−131.6%	$36.8M	$36.0M	−2.3%	−11.26%
Feb 18, 2026Q4 FY25	−$0.49	−$0.27	+44.9%	$33.4M	$36.6M	+9.5%	−3.79%

View details

Financial highlights

	Q1 FY25	Q2 FY25	Q3 FY25	Q4 FY25	Q1 FY26	Q2 FY26
Revenue	$17.3M	$17.7M	$23.6M	$36.6M	$36.0M	$46.5M
Gross profit	$7.3M	$7.3M	$14.0M	$21.7M	$23.3M	$30.2M
Operating income	−$10.6M	−$10.1M	−$6.2M	−$12.4M	−$9.7M	−$21.9M
Net income	−$10.4M	−$12.4M	−$7.4M	−$28.1M	−$23.1M	−$9.0M
Diluted EPS	−$0.80	−$0.94	−$0.53	−$1.75	−$1.36	−$0.52
Gross margin	42.4%	41.2%	59.5%	59.5%	64.8%	65.0%
Operating margin	-61.4%	-56.9%	-26.2%	-33.9%	-27.0%	-47.1%

Fiscal years (4-quarter sums)FY21 $275.9M · FY22 $152.8M · FY23 $21.6M · FY24 $30.6M · FY25 $95.1M

Revenue by geography · FY25

HONG KONG$23.1M · 98%

Rest Of The World$578.0K · 2%

Balance sheet, Jun 30, 2026Cash & short-term investments $109.4M · Total debt $682.0K · Total assets $153.7M · Shareholders' equity $93.0M

Dividends

No dividends on record.

Ownership

Institutions 7.16%1.22M sharesInsiders 14.10%2.40M sharesOther 78.74%13.39M shares

Shares outstanding 17.00M · Float 12.63M · 74.3% free float

Top shareholders13F · 13D/G · Form 4

Holder	Shares	% outstanding	Form	Filed
Danny Sheng Wu Yeung · director, officer: Chief Executive Officer	1.69M	9.96%	Form 4	Aug 24, 2026
Hoi Chun Lo · officer: Chief Financial Officer	566.0K	3.33%	Form 4	Aug 24, 2026
Prospect Capital Advisors, LLC	235.8K	1.39%	13F	Aug 14, 2026
Jane Street Group, LLC	225.1K	1.32%	13F	Aug 14, 2026
Goldman Sachs Group Inc	168.7K	0.99%	13F	Aug 14, 2026

Insider tradesForm 4

Date	Insider	Role	Shares	Avg price
Aug 25, 2026	Brian J. Rosin	officer: CFO of IM8 (US) LLC	+5,100	$22.80
Aug 24, 2026	Brian J. Rosin	officer: CFO of IM8 (US) LLC	+18,000	$21.19
Aug 24, 2026	Danny Sheng Wu Yeung	director, officer: Chief Executive Officer	+17,181	$21.23
Aug 20, 2026	Danny Sheng Wu Yeung	director, officer: Chief Executive Officer	+7,500	$18.31